Skip to main content

Table 1 Plackett–Burman design for screening of Primary parameters

From: Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach

Sr no. A B C D E F G H I J K
1 70 MeOH 10 25 5 1.2 5 c18 AF 10 230
2 50 MeOH 30 10 5 1.2 20 c18 AF 5 250
3 70 ACN 30 25 3 1.2 20 c8 AF 5 230
4 50 MeOH 10 25 5 0.5 20 c8 AA 5 230
5 50 ACN 30 10 5 1.2 5 c8 AA 10 230
6 50 ACN 10 25 3 1.2 20 c18 AA 10 250
7 70 ACN 10 10 5 0.5 20 c8 AF 10 250
8 70 MeOH 10 10 3 1.2 5 c8 AA 5 250
9 70 MeOH 30 10 3 0.5 20 c18 AA 10 230
10 50 MeOH 30 25 3 0.5 5 c8 AF 10 250
11 70 ACN 30 25 5 0.5 5 c18 AA 5 250
12 50 ACN 10 10 3 0.5 5 c18 AF 5 230
  1. A = Mobile phase ratio (Organic phase:Aqueous phase, v/v); B = Organic phase type, C = Temperature of column oven, °C; D = Degase time, min; E = pH of buffer; F = Flow rate, mL/min; G = Sample volume, μL; H = Column type; I = Buffer (AA ammonium acetate, AF ammonium formate); J = Buffer strength, mM; K = Detection wavelength, nm